Top

Published in:

01-08-2014 | Neuro-oncology (R Soffietti, Section Editor)

Role of Stereotactic Radiosurgery in Meningiomas and Vestibular Schwannomas

Authors: Jeffrey T. Jacob, MD, Michael J. Link, MD, Bruce E. Pollock, MD

Published in: Current Treatment Options in Neurology | Issue 8/2014

Opinion statement

Intracranial meningiomas and vestibular schwannomas (VS, aka acoustic neuromas) are typically benign, slow-growing, non-invasive neoplasms. The imaging and radiobiologic characteristics of these tumors make them good candidates for stereotactic radiosurgery (SRS), a technique that has been in use for over three decades. Patient selection is critical for successful SRS: small- to moderate-sized tumors can be effectively treated with SRS if the patient does not have symptoms related to mass effect. Factors related to tumor control in meningioma SRS include histology, history of prior surgery, and volume. Tumor control rates after SRS is significantly lower for patients with WHO grade II or III meningiomas compared to patients with WHO grade I meningiomas. The risk of radiation-related complications is higher for patients with larger tumors and tumors located over the convexities or along the falx. Patients with small-volume non-operated skull base or tentorial WHO grade I meningiomas typically have the best outcomes after SRS. Radiosurgery of sporadic VS provides a high tumor control rate (92–95 %), with less than a 5 % risk of facial weakness. Hearing preservation progressively declines for 10 years or more after SRS, and the primary factors related to long-term preservation of useful hearing are tumor size and pre-SRS hearing class. Radiosurgery remains an important option for patients with neurofibromatosis type 2, but tumor control is lower and the risk of cranial nerve deficits is greater when compared to patients with sporadic VS.

Cushing H, Eisenhardt L. In: Meningiomas: Their classification, regional behavior, life history, and surgical end results. Springfield: Charles C. Thomas; 1938.

Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry. 1957;20:22–39.PubMedCentralPubMedCrossRef

Couldwell WT, Kan P, Liu JK, et al. Decompression of cavernous sinus meningioma for preservation and improvement of cranial nerve function. Technical Note J Neurosurg. 2006;105:148–52.CrossRef

Di Maio S, Ramanathan D, Garcia-Lopez R, et al. Evolution and future of skull base surgery: the paradigm of skull base meningiomas. World Neurosurg. 2012;78:260–75.PubMedCrossRef

Dufour H, Muracciole X, Métellus P, et al. Long-term tumor control and functional outcome in patients with cavernous sinus meningiomas treated by radiotherapy with or without previous surgery: is there an alternative to aggressive tumor removal? Neurosurgery. 2001;48:285–96.PubMed

Klink DF, Sampath P, Miller NR, et al. Long-term visual outcome after nonradical microsurgery in patients with parasellar and cavernous sinus meningiomas. Neurosurgery. 2000;47:24–32.PubMed

Mathiesen T, Lindquist C, Kihlström L, et al. Recurrence of cranial base meningiomas. Neurosurgery. 1996;39:2–9.PubMedCrossRef

Stafford SL, Perry A, Suman VJ, et al. Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988. Mayo Clin Proc. 1998;73:936–42.PubMedCrossRef

Sughrue ME, Kane AJ, Shangari G, et al. The relevance of Simpson grade I and II resection in modern neurosurgical treatment of World Health Organization grade I meningiomas. J Neurosurg. 2010;113:1029–35.PubMedCrossRef

10.

Goldsmith BJ, Wara WM, Wilson CB, et al. Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. J Neurosurg. 1994;80:195–201.PubMedCrossRef

11.

Métellus P, Batra S, Karkar S, et al. Fractionated conformal radiotherapy in the management of cavernous sinus meningiomas: long-term functional outcome and tumor control at a single institution. Int J Radiat Oncol Biol Phys. 2010;78:836–43.PubMedCrossRef

12.

Pasquier D, Bijmolt S, Veninga T, et al. Atypical and malignant meningioma: outcome and prognostic factors in 119 irradiated patients. A multicenter, retrospective study of the Rare Cancer Network. Int J Radiat Oncol Biol Phys. 2008;71:1388–93.PubMedCrossRef

13.

Rosenberg LA, Prayson RA, Lee J, et al. Long-term experience with world health organization grade III (malignant) meningiomas at a single institution. Int J Radiat Oncol Biol Phys. 2009;74:427–32.PubMedCrossRef

14.

Slater JD, Loredo LN, Chung A, et al. Fractionated proton radiotherapy for benign cavernous sinus meningiomas. Int J Radiat Oncol Biol Phys. 2012;83:e633–7.PubMedCrossRef

15.

Colombo F, Casentini C, Cavedon C, et al. Cyberknife radiosurgery for benign meningiomas: short-term results in 199 patients. Neurosurgery. 2009;64:A7–13.PubMedCrossRef

16.

Kollová A, Liscák R, Novotný Jr J, et al. Gamma knife surgery for benign meningioma. J Neurosurg. 2007;2007:325–36.CrossRef

17.

Kondziolka D, Mathieu D, Lunsford LD, et al. Radiosurgery as definitive management of intracranial meningiomas. Neurosurgery. 2008;62:53–60.PubMedCrossRef

18.

Pollock BE, Stafford SL, Link MJ, et al. Single-fraction radiosurgery of benign intracranial meningiomas. Neurosurgery. 2012;71:604–13.PubMedCrossRef

19.••

Santacroce A, Waller M, Régis J, et al. Long-term tumor control of benign intracranial meningiomas after radiosurgery in a series of 4565 patients. Neurosurgery. 2012;70:32–9. The largest series (n = 4565) on single-fraction SRS of benign (WHO grade I) intracranial meningiomas. All the patients had at least five years of follow-up after SRS. Tumor control was higher for imaging-defined tumors vs. operated grade I tumors, for female vs. male patients, for sporadic vs. multiple meningiomas, and for skull base vs. convexity tumors.PubMedCrossRef

20.•

Pollock BE, Stafford SL, Link MJ, et al. Stereotactic radiosurgery of WHO grade II and III intracranial meningiomas: treatment results based on a 22-year experience. Cancer. 2012;118:1048–54. This study documents that tumor control is much worse after SRS of WHO grade II–III meningiomas compared to WHO grade I meningiomas. Tumor progression despite prior EBRT and larger tumor volume were negative predictors of tumor control and survival after SRS.PubMedCrossRef

21.

Chopra R, Kondziolka D, Niranjan A, et al. Long-term follow-up of acoustic schwannoma radiosurgery with marginal tumor doses of 12 to 13 Gy. Int J Radiat Oncol Biol Phys. 2007;68:845–51.PubMedCrossRef

22.

Link MJ, Driscoll CL, Foote RL, et al. Radiation therapy and radiosurgery for vestibular schwannomas: indications, techniques, and results. Otolaryngol Clin North Am. 2012;45(2):353–66.PubMedCrossRef

23.

Friedman WA, Bradshaw P, Myers A, et al. Linear accelerator radiosurgery for vestibular schwannomas. J Neurosurg. 2006;105:657–61.PubMedCrossRef

24.

Chang SD, Gibbs I, Sakamoto G, et al. Staged stereotactic irradiation for acoustic neuromas. Neurosurgery. 2005;56:1254–63.PubMedCrossRef

25.

Lederman G, Lowry J, Werthiem S, et al. Acoustic neuroma: potential benefits of fractionated stereotactic radiosurgery. Stereotact Funct Neurosurg. 1997;69:175–82.PubMedCrossRef

26.

Pollock BE. Management of vestibular schwannomas that enlarge after stereotactic radiosurgery: treatment recommendations based on a 15 year experience. Neurosurgery. 2006;58:241–8.PubMedCrossRef

27.

Yang I, Sughrue ME, Han S, et al. Facial nerve preservation after vestibular schwannoma gamma knife radiosurgery. J Neurooncol. 2009;93:41–8.PubMedCrossRef

28.

Yang I, Sughrue ME, Han S, et al. A comprehensive analysis of hearing preservation after radiosurgery for vestibular schwannoma. J Neurosurg. 2010;112:851–9.PubMedCrossRef

29.••

Carlson ML, Jacob JT, Pollock BE, et al. Long-term hearing outcomes following low-dose stereotactic radiosurgery for vestibular schwannoma: patterns of hearing loss and variables influencing audiometric decline. J Neurosurg. 2013;118:579–87. Study of patients undergoing low-dose (12-13 Gy) VS SRS with long-term longitudinal follow-up (median 9.3 years) and independent assessment of post-SRS hearing. By five years, less than 50 % of patients retained serviceable hearing. Factors related to hearing preservation included pre-SRS pure-tone average and tumor size.PubMedCrossRef

30.

Jacob JT, Carlson ML, Schiefer TK, et al. Significance of cochlear dose in the radiosurgical treatment of vestibular schwannoma: controversies and unanswered questions. Neurosurgery. 2014;74:466–74.PubMedCrossRef

31.

Pollock BE, Driscoll CL, Foote RL, et al. Patient outcomes after vestibular schwannoma management: a prospective comparison of microsurgical resection and stereotactic radiosurgery. Neurosurgery. 2006;59:77–85.PubMedCrossRef

32.

Mandl ES, Meijer OW, Slotman BJ, et al. Stereotactic radiation therapy for large vestibular schwannomas. Radiother Oncol. 2010;95:94–8.PubMedCrossRef

33.

Pollock BE, Link MK. Vestibular schwannoma radiosurgery after previous surgical resection or stereotactic radiosurgery. Prog Neurol Surg. 2008;21:163–8.PubMedCrossRef

34.

Pollock BE, Lunsford LD, Kondziolka D, et al. Vestibular schwannoma management. Part II. Failed radiosurgery and the role of delayed microsurgery. J Neurosurg. 1998;89:949–55.PubMedCrossRef

35.

Roche PH, Khalil M, Thomassin JM, et al. Surgical removal of vestibular schwannoma after failed gamma knife radiosurgery. Prog Neurol Surg. 2008;21:152–7.PubMedCrossRef

36.

Dewan S, Norén G. Retreatment of vestibular schwannomas with gamma knife surgery. J Neurosurg. 2008;109(Suppl):144–8.PubMed

37.

Yomo S, Arkha Y, Delsanti C, et al. Repeat gamma knife surgery for regrowth of vestibular schwannomas. Neurosurgery. 2009;64:45–52.CrossRef

38.

Mallory GW, Pollock BE, Foote RL, et al. Stereotactic radiosurgery for neurofibromatosis 2-associated vestibular schwannomas: toward dose optimization for tumor control and functional outcomes. Neurosurgery. 2014;74:292–300.PubMedCrossRef

39.

Carlson ML, Breen JT, Driscoll CL, et al. Cochlear implantation in patients with neurofibromatosis type 2: variables affecting auditory performance. Otol Neurotol. 2012;33:853–62.PubMedCrossRef

40.•

Leavitt JA, Stafford SL, Link MJ, Pollock BE. Long-term evaluation of radiation-induced optic neuropathy after single-fraction stereotactic radiosurgery. Int J Radiat Oncol Biol Phys. 2013;87:524–7. This study shows that the risk of a radiation-induced optic neuropathy after single-fraction SRS is very low (approximately 1 %) if the maximum point dose to the optic nerves or chiasm is ≤ 12 Gy.PubMedCrossRef

41.

Leenstra JL, Tanaka S, Kline RW, et al. Factors associated with endocrine deficits after stereotactic radiosurgery of pituitary adenomas. Neurosurgery. 2010;67:27–33.PubMedCrossRef

42.

Rowe J, Grainger A, Walton L, et al. Risk of malignancy after gamma knife stereotactic radiosurgery. Neurosurgery. 2007;60:60–6.PubMed

43.

Pollock BE, Lunsford LD, Kondziolka D, et al. Outcome analysis of acoustic neuroma management: a comparison of microsurgery and stereotactic radiosurgery. Neurosurgery. 1995;36:215–29.PubMedCrossRef

44.

Banerjee R, Moriarty J, Foote RL, Pollock BE. Comparison of the surgical and follow-up costs associated with microsurgical resection and stereotactic radiosurgery for vestibular schwannoma. J Neurosurg. 2008;108:1220–4.PubMedCrossRef

45.

Oya S, Kim S, Sade B, et al. The natural history of intracranial meningiomas. J Neurosurg. 2011;114:1250–6.PubMed

46.

Hashimoto N, Rabo CS, Okita Y, et al. Slower growth of skull base meningiomas compared with non-skull base meningiomas based on volumetric and biologic studies. J Neurosurg. 2012;116:574–80.PubMedCrossRef

47.

Stangerup SE, Cayé-Thomasen P, Tos M. The natural history of vestibular schwannoma. Otol Neurotol. 2006;27:547–52.PubMedCrossRef

48.•

Stangerup SE, Thomsen J, Tos M, et al. Long-term hearing preservation in vestibular schwannoma. Otol Neurotol. 2010;31:271–5. Large longitudinal study (n = 932) of VS patients undergoing observation. Fifty-nine percent of patients with good hearing (speech discrimination score of >70 %) retained good hearing at mean follow-up of 4.7 years. In patients with 100 % speech discrimination at diagnosis, 69 % had good hearing at 10 or more years of observation.PubMedCrossRef

Title: Role of Stereotactic Radiosurgery in Meningiomas and Vestibular Schwannomas
Authors: Jeffrey T. Jacob, MD
Michael J. Link, MD
Bruce E. Pollock, MD
Publication date: 01-08-2014
Publisher: Springer US
Published in: Current Treatment Options in Neurology / Issue 8/2014
Print ISSN: 1092-8480
Electronic ISSN: 1534-3138
DOI: https://doi.org/10.1007/s11940-014-0308-3

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Role of Stereotactic Radiosurgery in Meningiomas and Vestibular Schwannomas

Opinion statement

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Opinion statement

Please log in to get access to this content

Other articles of this Issue 8/2014

Repositioning Maneuvers for Benign Paroxysmal Positional Vertigo

Sleep Dysfunction and its Management in Parkinson’s Disease

Treatment Options for Thyroid Eye Disease

Advances in the Treatment of Obstructive Sleep Apnea